Article thumbnail

Elevated Serum Sorbitol and not Fructose in Type 2 Diabetic Patients

By Gregory M. Preston and Roberto A. Calle


Reductions in fasting serum fructose or erythrocyte sorbitol have been proposed as markers for early proof of mechanism in clinical development of aldose reductase (AR) inhibitors. However fructose is significantly impacted by meals and evaluation of erythrocyte sorbitol poses technical challenges. To more accurately assess the performance of these markers in biological samples, a gas chromatography-mass spectrometry assay was modified and validated. Serum was collected on three consecutive days from 13 healthy volunteers (HV) and 14 patients with type 2 diabetes mellitus (T2DM), and assayed for sorbitol and fructose using this assay. Serum fructose and sorbitol were relatively constant across the three days. Fasting fructose levels were comparable between the two groups (T2DM: 1.48 ± 0.49 mg/L; HV: 1.39 ± 0.38 mg/L, mean ± standard deviation, P = 0.61), but fasting sorbitol levels were significantly higher in diabetics (T2DM: 0.280 ± 0.163 mg/L; HV: 0.164 ± 0.044 mg/L, P = 0.02). Feeding resulted in a 5–6 fold increase in serum fructose levels, but only a 5%–10% increase in sorbitol. Only sorbitol remained significantly elevated pre- and post feeding in T2DM patients relative to HV. These data suggest that serum sorbitol may be a robust proof of mechanism biomarker and facilitate dose selection for clinical development of AR inhibitors

Topics: Short Report
Publisher: Libertas Academica
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic antonomic neuropathy in rats with streptozocin-induced diabetes. Exp Neurol.
  2. (2005). A sensitive assay of red cell sorbitol by high performance liquid chromatography: potential for diagnostic evaluation of diabetes. Clinica Chimica Acta.
  3. (2006). Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Healthy and Nutrition Examination Survey. Diabetes Care.
  4. (2008). Advanced glycation end products and sorbitol in blood from differently compensated diabetic dogs. Res Vet Sci.
  5. Cheng HM. The effect of oxidation on sorbitol pathway kinetics.
  6. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care.
  7. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
  8. (2008). Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vision.
  9. Fidarestat Clinical Pharmacology Study Group. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
  10. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
  11. (2002). Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care.
  12. Inhibition of sorbitol dehydrogenase: effects on vascular and neural dysfunction in streptozocin-induced diabetic rats.
  13. pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants.
  14. (2002). Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol.
  15. Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes.
  16. (2007). Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal.
  17. Red cell sorbitol, an indicator of diabetic control.
  18. (2004). the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care.
  19. the Kanazawa University Multicenter Diabetes Study Group. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
  20. The pathobiology of diabetic complications: a unifying mechanism.
  21. (1999). the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy.
  22. (1991). Trimethylsilyl-O-methyloxime derivatives for the measurement of [6,6−2H2]-D-glucose-enriched plasma samples by gas chromatography-mass spectrometry.